274 related articles for article (PubMed ID: 29743292)
1. Cholesterol negatively regulates IL-9-producing CD8
Ma X; Bi E; Huang C; Lu Y; Xue G; Guo X; Wang A; Yang M; Qian J; Dong C; Yi Q
J Exp Med; 2018 Jun; 215(6):1555-1569. PubMed ID: 29743292
[TBL] [Abstract][Full Text] [Related]
2. IL-9/STAT3/fatty acid oxidation-mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity.
Xiao L; Ma X; Ye L; Su P; Xiong W; Bi E; Wang Q; Xian M; Yang M; Qian J; Yi Q
J Clin Invest; 2022 Apr; 132(7):. PubMed ID: 35192544
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.
Lu Y; Hong B; Li H; Zheng Y; Zhang M; Wang S; Qian J; Yi Q
Proc Natl Acad Sci U S A; 2014 Feb; 111(6):2265-70. PubMed ID: 24469818
[TBL] [Abstract][Full Text] [Related]
4. Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation.
Visekruna A; Ritter J; Scholz T; Campos L; Guralnik A; Poncette L; Raifer H; Hagner S; Garn H; Staudt V; Bopp T; Reuter S; Taube C; Loser K; Huber M
Eur J Immunol; 2013 Mar; 43(3):606-18. PubMed ID: 23254356
[TBL] [Abstract][Full Text] [Related]
5. IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells.
Liu N; Jiang Y; Chen J; Nan H; Zhao Y; Chu X; Wang A; Wang D; Qin T; Gao S; Yi Q; Yue Y; Wang S
Cell Mol Immunol; 2019 Jul; 16(7):644-651. PubMed ID: 30275536
[TBL] [Abstract][Full Text] [Related]
6. TNF-a Is a Potent Stimulator of Tc9-Cell Differentiation.
Yang S; Chen J; Zhang H; Jiang Y; Qin T; Gao S; Yue Y; Wang S
J Immunother; 2020; 43(9):265-272. PubMed ID: 32842039
[TBL] [Abstract][Full Text] [Related]
7. TGF-β and IL-21 cooperatively stimulate activated CD8(+) T cells to differentiate into Tc17 cells.
Chen HW; Tsai JP; Yao TY; Hsieh CL; Chen IH; Liu SJ
Immunol Lett; 2016 Jun; 174():23-7. PubMed ID: 27085379
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in the differentiation and function of CD8⁺ T cells.
Mittrücker HW; Visekruna A; Huber M
Arch Immunol Ther Exp (Warsz); 2014 Dec; 62(6):449-58. PubMed ID: 24879097
[TBL] [Abstract][Full Text] [Related]
9. Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines.
Sad S; Mosmann TR
J Exp Med; 1995 Nov; 182(5):1505-15. PubMed ID: 7595220
[TBL] [Abstract][Full Text] [Related]
10. SUMO2 overexpression enhances the generation and function of interleukin-17-producing CD8⁺ T cells in mice.
Won TJ; Lee YJ; Hyung KE; Yang E; Sohn UD; Min HY; Lee DI; Park SY; Hwang KW
Cell Signal; 2015 Jun; 27(6):1246-52. PubMed ID: 25762490
[TBL] [Abstract][Full Text] [Related]
11. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.
Grange M; Verdeil G; Arnoux F; Griffon A; Spicuglia S; Maurizio J; Buferne M; Schmitt-Verhulst AM; Auphan-Anezin N
J Immunol; 2013 Oct; 191(7):3712-24. PubMed ID: 24006458
[TBL] [Abstract][Full Text] [Related]
12. Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of T
Bi E; Ma X; Lu Y; Yang M; Wang Q; Xue G; Qian J; Wang S; Yi Q
Sci Signal; 2017 Oct; 10(500):. PubMed ID: 29018172
[TBL] [Abstract][Full Text] [Related]
13. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.
Cerwenka A; Carter LL; Reome JB; Swain SL; Dutton RW
J Immunol; 1998 Jul; 161(1):97-105. PubMed ID: 9647212
[TBL] [Abstract][Full Text] [Related]
14. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy.
Lu Y; Wang Q; Yi Q
Oncoimmunology; 2014; 3():e28542. PubMed ID: 25054087
[TBL] [Abstract][Full Text] [Related]
16. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
17. Modulation of CD4+ and CD8+ T-Cell Function by Interleukin 19 and Interleukin 24 During Filarial Infections.
Anuradha R; Munisankar S; Dolla C; Kumaran P; Nutman TB; Babu S
J Infect Dis; 2016 Mar; 213(5):811-5. PubMed ID: 26486636
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
19. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
20. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
